BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-related biotech, with ARCH jumping in
Five years after forming and with more than $100 million already invested in the company, a biotech from BeiGene co-founder Xiaodong Wang is back with another whopping investment, this time at $200 million.
Sironax disclosed the Series B on Tuesday, saying the funds will bankroll studies of drugs for age-related degenerative diseases that include “regulated cell death, neuroprotective pathways and neuroinflammation.” Already in the clinic are two receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.